Angiotensin Receptor Blocker

Discontinuation of renin-angiotensin system inhibitor therapy before major noncardiac surgery did not appear to affect postoperative outcomes vs. treatment continuation, a speaker reported.

Testing the effectiveness of an innovative, clinic-level educational intervention to improve management of people with type 2 diabetes and CVD.

NEW ORLEANS — Implementing a coordinated care intervention in U.S. cardiology clinics led to a fourfold increase in the prescription of three groups of guideline-recommended therapies in adults with type 2 diabetes and atherosclerotic CVD.

NEW ORLEANS — Implementing a coordinated care intervention in U.S. cardiology clinics led to a fourfold increase in the prescription of three groups of guideline-recommended therapies in adults with type 2 diabetes and atherosclerotic CVD.

The majority of patients admitted for acute HF are eligible for foundational quadruple therapy and other medications, researchers reported in JACC: Heart Failure.

CHICAGO — An ultra-low-dose four-drug quad therapy may improve BP control among patients with hypertension, with no increased safety risk, compared with angiotensin receptor blocker monotherapy, according to a small, first-in-U.S. study.

Patients with hypertension who received angiotensin receptor blocking therapy had a significant decrease in incidence of epilepsy, researchers reported in JAMA Neurology.

Healio and Cardiology Today have compiled a list of the top read news in cardiology of March 2022.

In patients with HF with reduced ejection fraction, those with frailty had elevated risk for poor outcomes but less likelihood of being on optimal guideline-directed medical therapy, according to new data from the GUIDE-IT trial.

Cumulative exposure to high-dose angiotensin receptor blockers was associated with excess risk for cancer, according to a meta-regression analysis published in PLOS One.